Barclays initiated coverage of Altimmune (ALT) with an Overweight rating and $20 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune call volume above normal and directionally bullish
- Unusually active option classes on open January 22nd
- Enovix, Serve Robotics, EOG, Altimmune, Globalstar Shake Markets
- Midday Fly By: U.S. oil majors rise on Venezuela news, Versant completes spinoff
- Altimmune receives FDA breakthrough therapy designation for pemvidutide